Exchange: NASDAQ·Updated 02:24 PM EST

STOK Earnings

Latest Earnings Results: Q3 '26

Reported: Oct 29

Estimated EPS

-$0.93

Reported EPS

-$1.08

Surprise

-16.24%

Estimated Rev

$8.21M

Reported Rev

$11.26M

Surprise

+37.06%

• Reported GAAP EPS of -$1.08 down -66.15% YoY • Reported revenue of $11.26M up 5.93% YoY • Stoke Therapeutics said its $358.8M in cash, cash equivalents and marketable securities as of September 30, 2026 is expected to fund operations into early 2028.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$1.15
--
--
N/A
Q3 '26
-$0.93
-$1.08
-16.24%
MISSED
Q2 '26
-$0.80
-$0.93
-16.98%
MISSED
Q1 '26
-$0.81
-$0.79
2.17%
BEAT
Q4 '25
-$0.93
--
--
N/A

Advertisement|Remove ads.